Palisade Bio develops PALI-2108, a once-daily pill that releases a PDE4 inhibitor in the gut, for ulcerative colitis and Crohn's disease; it is not approved.
Palisade's case rests on PALI-2108, a once-daily oral prodrug that releases a PDE4 inhibitor in the lower gut. In a Phase 1 trial, all five ulcerative colitis patients had a clinical response and two reached remission. FDA cleared the IND for ASCENTRA-UC, a Phase 2 starting in the second half of 2026 with results in the second half of 2027. A Crohn's Phase 2 is planned for early 2027. Cash was $125.2 million at June 30.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: ASCENTRA-UC shows PALI-2108 works
Does PALI-2108 beat placebo on the primary endpoint in moderate to severe ulcerative colitis?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Palisade's PALI-2108 starts a colitis Phase 2, with cash into 2028
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.